Safety and Efficacy of Natalizumab in the Treatment of Crohn's Disease
Completed · Phase 3
Conditions studied: Crohn's Disease
In brief
The purpose of this study is to determine the safety and efficacy of natalizumab in individuals diagnosed with moderately to severely active Crohn's disease. It is thought that natalizumab may stop the movement of certain cells, known as white blood cells, into bowel tissue. These cells are thought to cause damage in the bowel leading to the symptoms of Crohn's disease.
Key facts
- Study ID
- NCT00032799
- Run by
- Biogen
- People needed
- 905
- Starts
- 2001-12-01
- Expected to finish
- 2003-09-01
- Last updated by the study team
- 2016-06-16
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- Elan Pharmaceuticals — San Diego, California, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.